| Suspended | CD34+ Enriched Transplants to Treat Myelodysplastic Syndrome NCT05617625 | Guenther Koehne | Phase 2 |
| Not Yet Recruiting | Kinetic Analysis of Immune Cells in Blood and Chronic Graft-Versus-Host Disease-Affected Tissues After Allogen NCT07235501 | City of Hope Medical Center | — |
| Not Yet Recruiting | Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of G NCT06996119 | City of Hope Medical Center | Phase 1 |
| Recruiting | Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma NCT07356245 | Jonathan Brammer | Phase 2 |
| Not Yet Recruiting | Framework for Optimizing, Refining, and Unifying Management of HSCT in Pediatric ALL NCT07297914 | Bambino Gesù Hospital and Research Institute | Phase 2 / Phase 3 |
| Recruiting | BPC2001 for the Prevention of Acute Graft-Versus-Host Disease Following Haploidentical Stem Cell Transplantati NCT07246031 | BioPhoenix Co., Ltd. | Phase 2 |
| Recruiting | Multidisciplinary Intervention for Adults With Chronic Graft-versus-host Disease NCT06910969 | Massachusetts General Hospital | N/A |
| Withdrawn | TCRαβ/CD19 Depletion of Stem Cell Grafts for Transplant NCT05968170 | Neena Kapoor, M.D. | N/A |
| Recruiting | A Study of Belumosudil in People at Risk of Developing Graft-Versus-Host Disease After a Stem Cell Transplant NCT07006506 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Recruiting | Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Vers NCT06815003 | City of Hope Medical Center | Phase 2 |
| Recruiting | Study Comparing Reduced Versus Standard Dose Post-transplantation Cyclophosphamide in Combination With Post-en NCT06705062 | Shanghai Jiao Tong University School of Medicine | Phase 3 |
| Recruiting | Evaluation of Rovadicitinib Compared to the Protocol Selected by Researchers in Third Line and Subsequent Stud NCT06682169 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 3 |
| Recruiting | Dose-Escalation Trial of Mesenchymal Stromal Cells in Patients With Medical Xerostomia NCT06392711 | University of Wisconsin, Madison | Phase 1 |
| Withdrawn | Extracorporeal Photopheresis and Mesenchymal Stem Cell Infusion for GVHD NCT05333029 | Molly Gallogly | Phase 2 |
| Recruiting | Study Testing Two Conditioning Regimen With a Single Prophylaxis of GVHD by Cyclophosphamide and Methotrexate NCT06252870 | Nantes University Hospital | Phase 2 |
| Unknown | Sequential Administration of WJ-MSCs for the Treatment of GvHD Refractory to Second Line Treatment NCT06304025 | Fundación Oftalmológica de Santander Clínica Carlos Ardila Lulle | Phase 1 / Phase 2 |
| Recruiting | Prospective Clinical Trial for Children With TCRαβ Depleted vs Traditional Haplo Identicle HSCT NCT06423131 | Sijia Gu | N/A |
| Recruiting | Ruxolitinib With and Without CTLA-4 Ig Abatacept for the Prophylaxis of Graft-Versus-Host Disease and Cytokine NCT06008808 | Washington University School of Medicine | Phase 1 |
| Recruiting | SYsteMatical Trained learnIng aLgorithms for Oral carcInogenesiS Interpretation by Optical Coherence Tomograph NCT06321003 | University of Palermo | — |
| Unknown | Physical Therapy in Patients Undergoing Allo-HSCT With cGVHD NCT06279585 | University of Seville | N/A |
| Not Yet Recruiting | Combination of ATG-based Conditioning Regimen and PTCy for GVHD Prevention in Allo-HSCT After PD-1 Blockade NCT06238245 | Beijing 302 Hospital | Phase 2 |
| Withdrawn | Correlation of Serum Gasdermin-D and NLRP-3 Inflammasome Levels With GVHD Biomarkers and Endothelial Damage Ma NCT06200441 | Ugur Arzu Kulu | — |
| Unknown | Letermovir Prophylaxis for Cytomegalovirus (CMV) in Patients With Graft-versus-host Disease NCT05969743 | Rabin Medical Center | Phase 2 |
| Active Not Recruiting | De-escalated Cyclophosphamide (PTCy) and Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis NCT05622318 | Medical College of Wisconsin | Phase 2 |
| Enrolling By Invitation | Posaconazole Tablet As Primary Prophylaxis of HSCT Patients with Gastrointestinal GVHD NCT06698211 | Institute of Hematology & Blood Diseases Hospital, China | — |
| Recruiting | Parametric Response Mapping (PRM) for the Detection of Chronic Lung Injury in Hematopoietic Cell Transplant Re NCT05866302 | University of Michigan Rogel Cancer Center | — |
| Completed | To Assess SHR0302 Oral Solutions and Tablets in Healthy Subjects Clinical Studies of Relative Bioavailability NCT05856058 | Jiangsu HengRui Medicine Co., Ltd. | Phase 1 |
| Recruiting | A PMS of Jakavi® in Patients With Steroid-Refractory Graft-versus-Host Disease (SR-GvHD) in Korea NCT05621733 | Novartis Pharmaceuticals | — |
| Active Not Recruiting | The Skin Microbiome in Graft Versus Host Disease NCT04231500 | University Hospital, Basel, Switzerland | — |
| Active Not Recruiting | Metabolome and Microbiome Impact on Acute GVHD in Recipients of Hematopoietic Transplant NCT05186857 | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla | — |
| Terminated | Expressive Writing in GVHD NCT05694832 | Northwestern University | EARLY_Phase 1 |
| Completed | Efficacy of Low-dose PT-Cy for Prevention of GVHD in Ambulatory Allogeneic HSCT NCT07319000 | Hospital Universitario Dr. Jose E. Gonzalez | Phase 2 |
| Terminated | ImmunoCARE: Rapid, Accurate COVID Testing to Reduce Hospitalization of Immunocompromised Individuals NCT05655546 | Scripps Translational Science Institute | N/A |
| Recruiting | A Study of Photobiomodulation (PBM) Therapy in People With Oral Graft-Versus-Host Disease (GVHD) After Stem Ce NCT05675930 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Unknown | A Prospective, Open Label, Dose-escalation, SAD/MAD, Multicenter, 24weeks, Phase I/IIa Clinical Trial to Evalu NCT05276076 | ViGenCell Inc. | Phase 1 / Phase 2 |
| Completed | The Effects and Safety of 5% Lifitegrast Ophthalmic Solution in Subjects With Dry Eye Disease in Ocular Graft- NCT04792580 | Richard W Yee, MD | EARLY_Phase 1 |
| Unknown | Intestinal Microbiome-based Research for the Prevention of Acute GVHD NCT05808985 | Soonchunhyang University Hospital | Phase 2 |
| Terminated | A Study of Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute Graft Versus H NCT05263999 | Equillium | Phase 3 |
| Active Not Recruiting | Post-Transplant Cyclophosphamide, Bortezomib and Abatacept for the Prevention of Graft-versus-Host-Disease (Gv NCT05289167 | Northwell Health | Phase 1 / Phase 2 |
| Unknown | Comparison of PT-Cy at a Dose of 25 mg/kg/Day and PT-Cy at a Dose of 50 mg/kg/Day in GVHD Prophylaxis NCT05158608 | National Research Center for Hematology, Russia | Phase 3 |
| Recruiting | PTCY Plus uhCG/EGF for Graft Versus Host Disease Prophylaxis NCT04886726 | Henry Ford Health System | Phase 1 |
| Completed | Ruxolitinib With Calcineurin Inhibitor and Methotrexate vs. Calcineurin Inhibitor Plus Methotrexate and Mycoph NCT04838704 | Zhejiang University | N/A |
| Completed | Neihulizumab for Standard-Risk Acute Graft Versus Host Disease (GVHD) NCT04144036 | Sameem M. Abedin, MD | Phase 1 |
| Unknown | A Single-arm Trial of Prophylactic Tocilizumab for Acute GVHD Prevention After Haploidentical HSCT. NCT04688021 | Yi Luo | Phase 2 |
| Recruiting | Relationship Between "FODMAPs" and "GVHD" NCT04660487 | The First Affiliated Hospital of Soochow University | — |
| Completed | PTCy and Ruxolitinib vs PTCy, Tacrolimus and MMF in MUD and Haploidentical HSCT NCT04669210 | St. Petersburg State Pavlov Medical University | Phase 2 |
| Completed | Cyclophosphamide, Abatacept, and Tacrolimus for GvHD Prevention NCT04503616 | NYU Langone Health | Phase 1 / Phase 2 |
| Terminated | HIgh Dose Thymoglobulin Instead of Cyclosporine With a Low Dose of Thymoglobulin for GVHD Prophylaxis NCT03456817 | AHS Cancer Control Alberta | Phase 2 |
| Completed | Baricitinib for the Prophylaxis of Graft-Versus-Host Disease After Peripheral Blood Hematopoietic Cell Transpl NCT04131738 | Washington University School of Medicine | Phase 1 |
| Unknown | Cryopreservation of White Blood Cells Before Their UVA Irradiation for Graft Versus Host Disease Treatment NCT03361254 | Central Hospital, Nancy, France | N/A |
| Active Not Recruiting | Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogenei NCT03842696 | University of Michigan Rogel Cancer Center | Phase 1 / Phase 2 |
| Recruiting | A Feasibility Study Using CLINIMACS® for Alpha/Beta T-Cell Depletion in Stem Cell Transplant NCT04337515 | Christopher Dvorak | N/A |
| Completed | RGI-2001 for the Prevention of Acute Graft-vs-Host Disease in Subjects Following Allogeneic Hematopoietic Stem NCT04014790 | Regimmune Corporation | Phase 2 |
| Active Not Recruiting | Acute GVHD Suppression Using Costimulation Blockade to Expand Non-malignant Transplant NCT03924401 | Emory University | Phase 2 |
| Recruiting | Safety and Efficacy of Fecal Microbiota Transplantation NCT04014413 | Chinese University of Hong Kong | N/A |
| Active Not Recruiting | Optimizing PTCy Dose and Timing NCT03983850 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Terminated | T Lymphocytes (LT) Expressing iCASP9 and ΔCD19 in Allogeneic Haematopoietic Transplantation. NCT02849886 | Centre Hospitalier Universitaire de Besancon | Phase 1 / Phase 2 |
| Unknown | Prevalence of Chronic Oral Graft Versus Host Disease Risk Factors in Pediatric Patients NCT03880214 | yasmeen magdi sholkamy | — |
| Completed | Itacitinib for Low Risk GVHD NCT03846479 | John Levine | Phase 2 |
| Completed | CD40-L Blockade for Prevention of Acute Graft-Versus-Host Disease NCT03605927 | H. Lee Moffitt Cancer Center and Research Institute | Phase 1 |
| Unknown | Prophylactic Donor Lymphocyte Infusion After Allo-PBSCT for Patients With Very High-risk Hematologic Malignanc NCT03771222 | Chinese PLA General Hospital | Phase 2 |
| Terminated | Study of Brimonidine Tartrate Nanoemulsion Eye Drops in Patients With Ocular Graft-vs-Host Disease NCT03591874 | Ocugen | Phase 3 |
| Terminated | Topical Ruxolitinib for Cutaneous Chronic Graft Versus Host Disease (cGVHD) NCT03395340 | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Phase 2 |
| Recruiting | Chronic Graft-versus-Host Disease in the Oral Cavity of Patients Following Allogeneic Hematopoietic Stem Cell NCT03602599 | National Institute of Dental and Craniofacial Research (NIDCR) | — |
| Recruiting | Post Transplant Cyclophosphamide in Matched Unrelated Donor Stem Cell Transplantation for Hematological Malign NCT03818334 | Hospital Israelita Albert Einstein | Phase 2 / Phase 3 |
| Completed | Cellular Stress Reactions During Graft-versus-host Disease NCT04558788 | University of Freiburg | — |
| Unknown | Anti T-lymphocyte Immunoglobulin With Post Transplant Cyclophosphamide to Prevent GVHD Post Allogeneic Transpl NCT03357159 | Sheba Medical Center | Phase 2 |
| Completed | A Proof of Concept Pilot Trial of Alpha-1-Antitrypsin for Pre-Emption Of Steroid-Refractory Acute GVHD NCT03459040 | John Levine | Phase 2 |
| Completed | Belimumab for Prevention of Chronic Graft-versus-Host Disease Following Allogeneic Hematopoietic Cell Transpla NCT03207958 | Washington University School of Medicine | Phase 1 |
| Completed | Detection of Graft Versus Host Disease With [18F]F-AraG NCT03367962 | CellSight Technologies, Inc. | Phase 1 |
| Terminated | Dynamic of Immunocompetent Populations in Patients Treated With Extracorporeal Photopheresis in Chronic Graft NCT03438643 | University Hospital, Lille | — |
| Completed | Topical Fibrinogen-Depleted Human Platelet Lysate in Patients With Dry Eye Secondary to Graft vs. Host Disease NCT03414645 | Cambium Bio Limited | Phase 1 / Phase 2 |
| Completed | An Open-Label Study of Defibrotide for the Prevention of Acute Graft-versus-Host-Disease (AGvHD) NCT03339297 | Jazz Pharmaceuticals | Phase 2 |
| Completed | Optimization of Antibiotic Treatment in Hematopoietic Stem Cell Receptors NCT03727113 | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla | — |
| Terminated | Post Transplant Cyclophosphamide (PTCY) as Sole Graft Versus Host Disease (GVHD) Prophylaxis for Matched Allot NCT03263767 | Nantes University Hospital | Phase 2 |
| Completed | Treatment of Patients With Teduglutide (GLP-2) for GVHD and Analysis of Paneth Cells of GVHD Patients NCT04290429 | University of Freiburg | EARLY_Phase 1 |
| Terminated | Gluten Free Diet in Preventing Graft Versus Host Disease in Patients Undergoing Donor Stem Cell Transplant NCT03102060 | Rutgers, The State University of New Jersey | N/A |
| Active Not Recruiting | Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus H NCT03192397 | Roswell Park Cancer Institute | Phase 1 / Phase 2 |
| Unknown | Changes in the Gut Microbiota of Patients Undergoing Allogeneic Stem Cell Transplantation (COLLECT) NCT03148197 | University of Cologne | — |
| Completed | Prevention of GVHD in Patients Treated With Allogeneic SCT: Possible Role of Extracorporeal Photophoresis NCT03204721 | Oslo University Hospital | N/A |
| Unknown | Low Dose ATG Plus Low Dose PTCy as GVHD Prophylaxis in Haplo-HSCT NCT03395860 | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Phase 2 |
| Completed | High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in P NCT03128359 | City of Hope Medical Center | Phase 2 |
| Unknown | The Effect of Human Leukocyte Antigen Macthing on Guiding Tacrolimus Regimen After Liver Transplantation NCT03147157 | The First Hospital of Jilin University | N/A |
| Terminated | A Phase 2/3 Study of GLASSIA for the Treatment of Acute GvHD NCT02956122 | Baxalta now part of Shire | Phase 2 / Phase 3 |
| Unknown | Chemotherapy and DLI for Prevention of Second Relapse in Patients With Relapsed Acute Leukemia After Allotrans NCT03297528 | Peking University People's Hospital | Phase 2 |
| Completed | Identification of Novel Targetable Kinases in SR-a GvHD NCT04342442 | University of Freiburg | — |
| Terminated | The Influence of TaKeTiNa Music Therapy, Traditional Chinese Acupuncture and Clown Theatrical Performance on Q NCT02976558 | University of Erlangen-Nürnberg Medical School | N/A |
| Withdrawn | Safety and Efficacy of Autologous PRP and PPP Eye Drops in the Treatment of Ocular GVHD NCT02561520 | Ladan Espandar | Phase 1 |
| Completed | CD45RA Depleted T-cell Infusion for Prevention of Infections After TCRab/CD19-depleted Allo-HSCT NCT02942173 | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | Phase 2 / Phase 3 |
| Completed | Phase II Trial of Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft-Versus-Host Disease (GVH NCT02663622 | Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Phase 2 |
| Terminated | Nonmyeloablative Conditioning and Transplantation for Patients With Refractory Systemic Lupus Erythematosus (S NCT02080195 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 1 / Phase 2 |
| Terminated | Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Pa NCT02877082 | Emory University | Phase 2 |
| Completed | Abatacept for GVHD Prophylaxis After Hematopoietic Stem Cell Transplantation for Pediatric Sickle Cell Disease NCT02867800 | Monica Bhatia | Phase 1 |
| Completed | Early Detection of Mucosal Abnormalities in Graft-versus-host Disease NCT02707354 | Nantes University Hospital | N/A |
| Completed | Single-centre Study of Everolimus as GvHD Prophylaxis After Post-Transplantation Cyclophosphamide After Alloge NCT02812940 | University of Cologne | Phase 2 |
| Completed | Panobinostat (LBH589): Acute Graft Versus Host Disease (aGVHD) Prevention NCT02588339 | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 |
| Withdrawn | Tocilizumab for Chronic Graft-versus-Host Disease Treatment NCT02174263 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Nutrition and Outcomes of Hematopoietic Cell Transplantation (HCT) NCT03419078 | Imperial College Healthcare NHS Trust | — |
| Withdrawn | Donor Regulatory T Cells in Treating Patients With Visceral Acute Graft-versus-Host Disease After Stem Cell Tr NCT02526329 | Everett Meyer | Phase 1 |
| Completed | Irradiated Blood Versus Non Irradiated Blood Transfusions in Craniosynostosis Repair NCT02483702 | Valley Anesthesiology Consultants | N/A |
| Completed | Adoptive Immunotherapy With Activated Marrow Infiltrating Lymphocytes and Cyclophosphamide Graft-Versus-Host D NCT02342613 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 1 |
| Completed | Comparison of Gut Microbiota, Inflammation and Symptoms Following Allogeneic HSCT NCT02398708 | University of Florida | — |
| Active Not Recruiting | CINC424A2X01B Rollover Protocol NCT02386800 | Novartis Pharmaceuticals | Phase 4 |
| Completed | Donor Stem Cell Transplant Followed by Cyclophosphamide in Treating Patients With Hematological Diseases NCT02248597 | Wake Forest University Health Sciences | Phase 2 |
| Terminated | Early Treatment of Acute Graft Versus Host Disease With Bone Marrow-Derived Mesenchymal Stem Cells and Cortico NCT02379442 | National Heart, Lung, and Blood Institute (NHLBI) | Phase 1 / Phase 2 |
| Withdrawn | Lymphocyte Profiles and Activation Status in Patients With Graft-Versus-Host Disease NCT01988701 | Ohio State University Comprehensive Cancer Center | — |
| Completed | Allogenic Bone Marrow Mesenchymal Stem Cells Infusion in Patients With Steroid-refractory GVHD NCT02824653 | National Institute of Blood and Marrow Transplant (NIBMT), Pakistan | Phase 1 / Phase 2 |
| Completed | BMT Autologous MSCs for GvHD NCT02359929 | Emory University | Phase 1 |
| Completed | Phase II Trial of Natalizumab + Prednisone for Initial Therapy of Acute GI GVHD NCT02176031 | Dana-Farber Cancer Institute | Phase 2 |
| Terminated | Biomarkers in Acute Graft-Versus-Host Disease and Extracorporeal Photopheresis Added to Investigator Chosen Th NCT02322190 | National Cancer Institute (NCI) | Phase 2 |
| Unknown | Carfilzomib for the Prevention of Graft Versus Host Disease NCT01991301 | Sheba Medical Center | Phase 1 |
| Terminated | Romidepsin in Treating Patients With Steroid-Refractory Graft-versus-Host Disease NCT02203578 | Rutgers, The State University of New Jersey | N/A |
| Completed | Ex-vivo Expanded Donor Regulatory T Cells for Prevention of Acute Graft-Versus-Host Disease NCT01795573 | H. Lee Moffitt Cancer Center and Research Institute | Phase 1 |
| Completed | Safety of Post-transplant Alpha-beta Depleted T-cell Infusion Following Haploidentical Stem Cell Transplant (H NCT02193880 | Ayman Saad | N/A |
| Completed | Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies NCT02145403 | University of Michigan Rogel Cancer Center | Phase 1 / Phase 2 |
| Terminated | Prospective Outcomes of Second-Line Therapy in Acute Graft-Versus-Host Study Including ECP (POSTAGE) NCT02151539 | Vanderbilt-Ingram Cancer Center | — |
| Completed | Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Chronic Graft Versus Host Disease NCT02195869 | Pharmacyclics LLC. | Phase 1 / Phase 2 |
| Terminated | Low-Dose Total Lymphoid Irradiation in Treating Patients With Refractory Chronic Graft-versus-Host Disease Aft NCT02109809 | Wake Forest University Health Sciences | N/A |
| Completed | Prevention of Ocular Graft-Versus-Host Disease With Topical Cyclosporine in Recipients of Allogeneic HSCT NCT02144025 | Hospital Universitario Dr. Jose E. Gonzalez | Phase 2 |
| Unknown | Maraviroc-Based GVHD Prophylaxis in HLA-Unrelated and HLA-Mismatched Related Transplantation NCT02799888 | Affiliated Hospital to Academy of Military Medical Sciences | Phase 2 |
| Terminated | Phase I Trial of LDE225 for Steroid-refractory Chronic GVHD After Allogeneic HSCT NCT02086513 | Massachusetts General Hospital | Phase 1 |
| Completed | In Vivo Treg Expansion and Graft-Versus-Host Disease Prophylaxis NCT01927120 | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 |
| Withdrawn | Mesenchymal Stem Cells as a Treatment for Oral Complications of Graft-versus-host Disease NCT02055625 | Karolinska Institutet | Phase 1 / Phase 2 |
| Completed | Bridging Pediatric and Adult Biomarkers in Graft-Versus-Host Disease NCT02194439 | Indiana University | — |
| Completed | Phase 1 Infused Donor T Regulatory Cells in Steroid Dependent/Refractory Chronic GVHD NCT01911039 | Laura Johnston | Phase 1 |
| Completed | Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hemato NCT01789255 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Collection of Saliva and/ or Peripheral Blood From Healthy Volunteers for Research NCT01851382 | National Cancer Institute (NCI) | — |
| Completed | G-CSF Moblized Peripheral Harvest for Poor Engraftment After Stem Cell Transplantation NCT01857336 | Peking University People's Hospital | N/A |
| Completed | Lactobacillus Rhamnosus GG in Reducing Incidence of Graft-Versus-Host Disease in Patients Who Have Undergone D NCT02144701 | Rutgers, The State University of New Jersey | N/A |
| Completed | Clinical and Biomarker Study of the Efficacy of Extracorporeal Photopheresis in Graft-versus-host Disease NCT03124056 | Fundación para la Investigación del Hospital Clínico de Valencia | — |
| Completed | Standard of Care vs. Bortezomib in Graft-Versus Host Disease After Hematopoietic Stem Cell Transplant NCT01754389 | Dana-Farber Cancer Institute | Phase 2 |
| Completed | Efficacy and Safety of Nilotinib in Patients With a Chronic Disease of the Graft Against the Host NCT02891395 | University Hospital, Lille | Phase 2 |
| Withdrawn | Brentuximab Vedotin in Treating Patients With Steroid-Resistant Acute Graft-Versus-Host Disease NCT01616680 | Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium | Phase 2 |
| Unknown | Cannabidiol for Graft Versus Host Disease (GVHD) Prophylaxis in Allogeneic Stem Cell Transplantation NCT01385124 | Rabin Medical Center | Phase 1 / Phase 2 |
| Completed | Pomalidomide for Chronic Graft-versus-Host Disease NCT01688466 | National Cancer Institute (NCI) | Phase 2 |
| Unknown | Safety and Efficacy of Cannabidiol for Grade I/II Acute Graft Versus Host Disease (GVHD) After Allogeneic Stem NCT01596075 | Rabin Medical Center | Phase 1 / Phase 2 |
| Completed | Bortezomib in Patients With Chronic Graft Versus Host Disease NCT01672229 | Mehrdad Abedi, MD | Phase 1 |
| Completed | Bandage Lenses in Treating Patients With Ocular Graft-Versus-Host Disease NCT01616056 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Extension Study (Extended Access) of Cyclosporine Inhalation Solution (CIS) in Lung Transplant and Hematopoiet NCT01273207 | National Heart, Lung, and Blood Institute (NHLBI) | Phase 2 |
| Completed | Transdermal Patch to Monitor Inflammatory Biomarkers of GVHD NCT02511782 | Children's Hospital Medical Center, Cincinnati | N/A |
| Unknown | Umbilical Cord Blood-derived Mesenchymal Stem Cells for the Treatment of Steroid-refractory Acute or Chronic G NCT01549665 | Samsung Medical Center | Phase 1 / Phase 2 |
| Terminated | Infliximab and Basiliximab for Treatment of Steroid Refractory Acute Graft Versus Host Disease NCT01485055 | Nationwide Children's Hospital | Phase 2 |
| Completed | Bone Marrow Stromal Cell Infusions for Stem Cell Transplant Complications NCT01633229 | National Heart, Lung, and Blood Institute (NHLBI) | Phase 1 |
| Unknown | Donor Lymphocyte Infusion After Stem Cell Transplant in Treating Patients With Haematological Cancers NCT01240525 | University College, London | Phase 2 |
| Completed | Outcomes of Cutaneous T-Cell Lymphoma and Graft-Versus-Host Disease With Extracorporeal Photopheresis Treatmen NCT01460914 | Dartmouth-Hitchcock Medical Center | — |
| Active Not Recruiting | Minitransplants With HLA-matched Donors : Comparison Between 2 GVHD Prophylaxis Regimens NCT01428973 | University of Liege | Phase 2 |
| Completed | Intravenous Administration of RGI-2001 in Patient Undergoing Allogenic Hematopoietic Stem Cell Transplantation NCT01379209 | Regimmune Corporation | Phase 1 / Phase 2 |
| Unknown | T&B Depletion Non Malignant NCT01810926 | Franco Locatelli | Phase 2 |
| Terminated | In-vivo Regulatory T Cell Enhancement With Cyclophosphamide and Sirolimus NCT01453140 | Hackensack Meridian Health | Phase 1 / Phase 2 |
| Terminated | Mesenchymal Stromal Cells as Treatment of Chronic Graft-versus-host Disease NCT01522716 | Karolinska Institutet | Phase 1 |
| Completed | The Natural History of Graft-Versus-Host Disease in the Eyes NCT01369914 | National Eye Institute (NEI) | — |
| Completed | Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease NCT01309997 | Lee, Stephanie | Phase 2 |
| Unknown | Tacrolimus and Mycophenolate Mofetil as Post-Grafting Immunosuppression NCT02178683 | Colorado Blood Cancer Institute | Phase 3 |
| Completed | Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Tran NCT01233921 | Martin, Paul | N/A |
| Terminated | Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Underg NCT01116232 | Barbara Ann Karmanos Cancer Institute | Phase 2 |
| Completed | Pilot Study: Patients With Chronic Active Graft Versus Host Disease That Have Failed or Not Tolerated Standard NCT01174277 | University of Kansas Medical Center | — |
| Completed | Test Extracorporeal Photopheresis (ECP) Treatment Before/After Allogeneic Bone Marrow Transplant (BMT) or Peri NCT01174940 | University of Kansas Medical Center | EARLY_Phase 1 |
| Completed | Pharmacokinetics-based Mycophenolate Mofetil Dosing for GVHD Prevention NCT01487577 | University of Pittsburgh | Phase 2 |
| Completed | Multicenter Clinical Trial for the Evaluation of Mesenchymal Stem Cells From Adipose Tissue in Patients With C NCT01222039 | Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud | Phase 1 / Phase 2 |
| Completed | Study of First Line Treatment of Chronic Graft Versus Host Disease With the Association of Ciclosporine, Corti NCT01135641 | Nantes University Hospital | Phase 2 |
| Terminated | A Study of Rituximab Combined With Prednisone for the Initial Treatment of Chronic Graft Versus Host Disease ( NCT01066598 | University Health Network, Toronto | Phase 2 |
| Completed | Histone Deacetylase Inhibitor LBH589 in Addition to Corticosteroids in Patients With Acute Graft Versus Host D NCT01111526 | H. Lee Moffitt Cancer Center and Research Institute | Phase 1 / Phase 2 |
| Completed | Acute Graft-versus-Host Disease Treatment (BMT CTN 0802) NCT01002742 | Medical College of Wisconsin | Phase 3 |
| Terminated | Selective Depletion of CD45RA+T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of NCT00914940 | Fred Hutchinson Cancer Center | Phase 2 |
| Terminated | Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer NCT01044745 | University of Nebraska | Phase 2 |
| Unknown | Safety and Efficacy Study of Allogenic Mesenchymal Stem Cells to Treat Extensive Chronic Graft Versus Host Dis NCT00972660 | Guangdong Provincial People's Hospital | Phase 2 |
| Unknown | Allogeneic Mesenchymal Stem Cell for Graft-Versus-Host Disease Treatment NCT00749164 | Hadassah Medical Organization | Phase 1 / Phase 2 |
| Unknown | T-Lymphocyte Infusion or Standard Therapy in Treating Patients at Risk of Cytomegalovirus Infection After a Do NCT00986557 | University Hospital Birmingham | Phase 2 |
| Unknown | Ocular Graft Versus Host Disease After Hematopoietic Stem Cell Transplantation in Adults NCT00912067 | Sheba Medical Center | — |
| Unknown | Open-Label Study Designed to Evaluate the Safety and Preliminary Efficacy of ApoCell for the Prevention of Acu NCT00524784 | Hadassah Medical Organization | Phase 1 / Phase 2 |
| Unknown | Extracorporeal Photopheresis in Children and Young Adults With Refractory Acute Graft Versus Host Disease NCT00824954 | University Hospital, Clermont-Ferrand | Phase 2 |
| Completed | Low-Dose Prednisone or Methylprednisolone in Treating Patients With Newly Diagnosed Acute Graft-versus-Host Di NCT00929695 | Fred Hutchinson Cancer Center | Phase 3 |
| Completed | Maraviroc in Patients Undergoing Non-Myeloablative Allogeneic Stem-Cell Transplantation NCT00948753 | Abramson Cancer Center at Penn Medicine | Phase 1 / Phase 2 |
| Completed | Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Pro NCT00639717 | University of Michigan Rogel Cancer Center | Phase 2 |
| Completed | Exploratory Study of Natural Killer Cells in Human Skin NCT00824889 | Assistance Publique Hopitaux De Marseille | N/A |
| Completed | Treatment of Steroid Resistant GVHD by Infusion MSC NCT00827398 | N.M. Wulffraat | Phase 1 / Phase 2 |
| Completed | Voriconazole Pharmacokinetics in Children With Gastrointestinal Graft Versus Host Disease NCT00792246 | Phillip Brian Smith | Phase 1 |
| Completed | Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor NCT00755040 | Vanderbilt-Ingram Cancer Center | Phase 3 |
| Completed | Alemtuzumab and Cyclosporine for the Prevention of Graft vs Host Disease After Stem Cell Transplants NCT00775632 | University Health Network, Toronto | Phase 2 |
| Withdrawn | Natural History and Pathophysiology of Gastrointestinal Graft-versus-Host Disease NCT00723593 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | — |
| Terminated | Alemtuzumab Use (MabCampath®) in Hematopoietic Transplant of Unrelated Donor With Reduced Intensity Conditioni NCT00781781 | CABYC | Phase 2 |
| Unknown | Multi Donor Mismatched Stem Cell Transplantation (MDT) NCT00716690 | Hadassah Medical Organization | Phase 1 / Phase 2 |
| Terminated | Immunologic Diagnostic Blood Test in Predicting Side-Effects in Patients Undergoing a Donor Stem Cell Transpla NCT00813501 | City of Hope Medical Center | — |
| Terminated | Donor T Cells in Treating Patients With High-Risk Hematologic Cancer Undergoing Donor Peripheral Blood Stem Ce NCT00725062 | Masonic Cancer Center, University of Minnesota | Phase 1 |
| Terminated | A Study to Evaluate the Effect of ATG-F on Engraftment, Graft Versus Host Disease (GVHD) and Graft Versus Leuk NCT00616954 | Hadassah Medical Organization | Phase 3 |
| Terminated | Lenalidomide (Revlimid®) as Second Line Therapy in Patients With Chronic Graft-Vs-Host Disease (GVHD) NCT00675441 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Low-Intensity Stem Cell Transplantation With Multiple Lymphocyte Infusions to Treat Advanced Kidney Cancer NCT00923845 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Rapamycin for Prevention of Chronic Graft-Versus-Host Disease NCT00623012 | Yale University | Phase 1 / Phase 2 |
| Completed | Study to Assess the Safety and Efficacy of Tacrolimus (Prograf Capsule/Injection) and Methotrexate (MTX) Combi NCT02660684 | Astellas Pharma Korea, Inc. | Phase 4 |
| Completed | Efficacy and Safety of Prochymal® Infusion in Combination With Corticosteroids for the Treatment of Newly Diag NCT00562497 | Mesoblast, Inc. | Phase 3 |
| Completed | Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Under NCT00513474 | Massachusetts General Hospital | Phase 1 |
| Unknown | Stem Cell Transplant in Treating Patients With Hematological Cancer or Other Disorders NCT00740467 | Institut Paoli-Calmettes | Phase 2 |
| Completed | Analysis of the Clinical and Histological Correlation of Oral Graft-Versus-Host-Disease (GVHD) NCT00898885 | University of Sao Paulo | — |
| Recruiting | Mesenchymal Stem Cell Infusion as Treatment for Steroid-Resistant Acute Graft Versus Host Disease (GVHD) or Po NCT00603330 | University of Liege | Phase 2 |
| Completed | Photopheresis for the Treatment of Acute Graft Versus Host Disease NCT00609609 | M.D. Anderson Cancer Center | Phase 2 |
| Terminated | Visilizumab for the Prevention of Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantatio NCT00720629 | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 |
| Completed | A Phase II Study of Allo-HCT for B-Cell NHL Using Zevalin, Fludarabine and Melphalan NCT00577278 | City of Hope Medical Center | Phase 2 |
| Unknown | Mesenchymal Stem Cells Infusion for aGVHD Prophylaxis Transplantation NCT01941394 | National Research Center for Hematology, Russia | Phase 2 |
| Terminated | Alemtuzumab, Busulfan, and Cyclophosphamide Followed By a Donor Stem Cell Transplant in Treating Patients With NCT00555048 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Completed | Randomized Trial Comparing Sirolimus and Tacrolimus Versus Cyclosporine and Methotrexate as Graft-versus-host NCT00993343 | Karolinska Institutet | Phase 3 |
| Completed | Ultra-Low Dose Interleukin-2 for Refractory Chronic Graft Versus Host Disease NCT00529035 | Dana-Farber Cancer Institute | Phase 1 |
| Terminated | Umbilical Cord Blood T-Regulatory Cell Infusion Followed by Donor Umbilical Cord Blood Transplant in Treating NCT00376519 | Masonic Cancer Center, University of Minnesota | Phase 1 |
| Completed | Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoi NCT00589563 | City of Hope Medical Center | Phase 2 |
| Completed | High-Dose Cyclophosphamide for Steroid Refractory GVHD NCT00492921 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 |
| Completed | Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem NCT00489203 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients Wit NCT00438958 | The Canadian Blood and Marrow Transplant Group | Phase 3 |
| Completed | Tacrolimus and Methotrexate With or Without Sirolimus in Preventing Graft-Versus-Host Disease in Young Patient NCT00382109 | Children's Oncology Group | Phase 3 |
| Terminated | Study of Opebacan in Patients Undergoing Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSC NCT00454155 | XOMA (US) LLC | Phase 1 / Phase 2 |
| Completed | Collecting and Storing Tissue and DNA Samples From Patients Undergoing a Donor Stem Cell Transplant NCT00900406 | Vanderbilt-Ingram Cancer Center | — |
| Terminated | Efalizumab in Treating Patients With Graft-Versus-Host Disease of the Skin That Did Not Respond to Previous St NCT00489216 | UNC Lineberger Comprehensive Cancer Center | N/A |
| Terminated | Donor Peripheral Stem Cell Transplant and Donor Natural Killer Cell Transplant After Total-Body Irradiation, T NCT00450983 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Clofarabine, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-R NCT00423514 | Memorial Sloan Kettering Cancer Center | Phase 1 / Phase 2 |
| Terminated | Everolimus in Combination With Cyclosporine A and Prednisolone for the Treatment of Graft Versus Host Disease NCT00373815 | University Hospital Tuebingen | Phase 1 |
| Completed | Efficacy and Safety of Adult Human Mesenchymal Stem Cells to Treat Steroid Refractory Acute Graft Versus Host NCT00366145 | Mesoblast, Inc. | Phase 3 |
| Completed | Feasibility Study of Collecting Multicenter Chronic GVHD Data NCT00506233 | M.D. Anderson Cancer Center | — |
| Completed | Alemtuzumab and Glucocorticoids in Treating Newly Diagnosed Acute Graft-Versus-Host Disease in Patients Who Ha NCT00410657 | Fred Hutchinson Cancer Center | Phase 2 |
| Terminated | Alefacept for Prevention of Graft Versus Host Disease (GVHD) NCT00361413 | Hadassah Medical Organization | Phase 3 |
| Completed | Fludarabine and Busulfan Followed by Donor Peripheral Stem Cell Transplant and Antithymocyte Globulin, Tacroli NCT00346359 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Experience of Having Chronic Graft-Versus-Host Disease NCT00353106 | M.D. Anderson Cancer Center | — |
| Completed | Tacrolimus and Sirolimus as Prophylaxis After Allogenic Non-myeloablative Peripheral Blood Stem Cell Transplan NCT00282282 | Dana-Farber Cancer Institute | Phase 2 |
| Completed | Trial to Evaluate Palifermin in the Reduction of Acute Graft Versus Host Disease in Patients With Hematologic NCT00189488 | Swedish Orphan Biovitrum | Phase 2 |
| Completed | Safety and Efficacy of Prochymal for the Salvage of Treatment-Refractory Acute GVHD Participants NCT00284986 | Mesoblast, Inc. | Phase 2 |
| Completed | Study on the Safety and Effectiveness of VELCADE® in the Treatment of Graft-Versus-Host Disease NCT00408928 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 2 |
| Completed | Tacrolimus and Mycophenolate Mofetil (MMF) in GVHD Prophylactic Regimen Compared to Tacrolimus and Methotrexat NCT00360685 | H. Lee Moffitt Cancer Center and Research Institute | N/A |
| Terminated | Treatment of Single or Double Umbilical Cord Trans + Graft-versus-host Disease (GVHD) Prophylaxis w/ Tacrolimu NCT00608517 | Vanderbilt-Ingram Cancer Center | N/A |
| Unknown | Early Diagnosis of Aspergillosis in Patients at High Risk of Fungal Infection Caused by Treatment for Hematolo NCT00462657 | St. Bartholomew's Hospital | N/A |
| Completed | Busulfan, Cyclophosphamide, & Antithymocyte Globulin Followed by Stem Cell Transplant in Treating Hematologic NCT00611351 | University of Nebraska | Phase 2 |
| Completed | Measurements of Resting Energy Expenditure in Patients With or at Risk of Developing Graft Versus Host Disease NCT00600314 | Ann & Robert H Lurie Children's Hospital of Chicago | — |
| Unknown | Dendritic Cells in Patients Following Allogeneic Hematopoietic Stem Cell Transplantation NCT00450268 | Technische Universität Dresden | — |
| Completed | Campath-1H + FK506 and Methylprednisolone for GVHD NCT00109993 | Case Comprehensive Cancer Center | Phase 2 |
| Completed | Study of Etanercept for the Prevention of Complications Resulting From Hematopoietic Stem Cell Transplantation NCT00141739 | University of Michigan Rogel Cancer Center | Phase 2 |
| Completed | A Study to Assess the Safety and Efficacy of a Tacrolimus New Oral Formulation (MR4) in BMT Patients-Extension NCT00189748 | Astellas Pharma Inc | Phase 2 |
| Completed | Tacrolimus and Mycophenolate Mofetil in Preventing Acute Graft-Versus-Host Disease in Patients With Advanced H NCT00096096 | Fred Hutchinson Cancer Center | Phase 2 |
| Unknown | Antithymocyte Globulin and Cyclosporine in Preventing Graft-Versus-Host Disease in Patients Undergoing Chemoth NCT00093587 | Jonsson Comprehensive Cancer Center | N/A |
| Terminated | G-CSF-Treated Donor Bone Marrow Transplant in Treating Patients With Hematologic Disorders NCT00253552 | OHSU Knight Cancer Institute | N/A |
| Completed | Infliximab for the Prevention of Graft-versus-Host Disease Following Allogenic Hematopoietic Stem Cell Transpl NCT00201799 | Ohio State University Comprehensive Cancer Center | Phase 2 |
| Completed | Budesonide for Prevention of Acute Gastrointestinal GVHD Following Allogenic Stem Cell Transplantation NCT00180089 | Technische Universität Dresden | Phase 3 |
| Completed | Cyclosporine Dose Adjustment According to Calcineurin Activity After Allogeneic Hematopoietic Stem-cell Transp NCT00948727 | Assistance Publique - Hôpitaux de Paris | Phase 2 |
| Terminated | Effectiveness of Topical Thalidomide to Treat Chronic Graft-Versus-Host-Disease Related Stomatitis NCT00075023 | National Institute of Nursing Research (NINR) | Phase 2 |
| Terminated | Fludarabine, Cyclophosphamide, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil i NCT00255684 | University of Rochester | N/A |
| Completed | Pentostatin in Treating Patients With Refractory Chronic Graft-Versus-Host Disease NCT00074035 | Alliance for Clinical Trials in Oncology | Phase 2 |
| Completed | Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Un-Related Stem Cell Transplantation NCT00144677 | Dana-Farber Cancer Institute | Phase 2 |
| Completed | The Use of Etanercept (Enbrel®) in the Treatment of Acute Graft-Versus-Host Disease NCT00141713 | University of Michigan Rogel Cancer Center | Phase 2 |
| Completed | Donor White Blood Cell Infusions and Interleukin-2 in Treating Patients Who Are Undergoing an Autologous Stem NCT00248430 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Completed | Phase II Trial of Pentostatin in Steroid Refractory Acute Graft Versus Host Disease NCT00201786 | Ohio State University Comprehensive Cancer Center | Phase 2 |
| Completed | Extracorporeal Photopheresis for Acute Graft Versus Host Disease NCT00179855 | Ann & Robert H Lurie Children's Hospital of Chicago | Phase 2 / Phase 3 |
| Completed | Sirolimus, Tacrolimus, and Methotrexate in Preventing Acute Graft-Versus-Host Disease in Patients With Hematol NCT00089037 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Terminated | Minor Histocompatibility Vaccination After Allogeneic Stem Cell Transplantation for Advanced Hematologic Malig NCT00943293 | University of Chicago | Phase 1 |
| Completed | Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Ce NCT00096161 | Fred Hutchinson Cancer Center | Phase 2 |
| Terminated | Tissue Repair in Stem Cell Transplant Recipients NCT00501228 | M.D. Anderson Cancer Center | N/A |
| Completed | Laboratory-Treated Donor Bone Marrow in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant fo NCT00265837 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 3 |
| Completed | Combination Chemotherapy and Antithymocyte Globulin in Reducing Graft-Versus-Host Disease in Patients Undergoi NCT00054340 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Completed | Recombinant Human Keratinocyte Growth Factor in Unrelated and Related Transplants NCT00056875 | University of Michigan | Phase 1 / Phase 2 |
| Completed | Cyclophosphamide and/or Mycophenolate Mofetil With or Without Tacrolimus in Treating Patients Who Are Undergoi NCT00255710 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 1 |
| Completed | Tacrolimus, Sirolimus and Methotrexate as Graft Versus Host Disease Prophylaxis After Blood Stem Cell Transpla NCT00146614 | Dana-Farber Cancer Institute | Phase 2 |
| Completed | Safety and Efficacy Study of Photopheresis With UVADEX to Prevent Graft-versus-Host Disease NCT00054600 | Mallinckrodt | Phase 2 |
| Completed | Safety and Efficacy Study of Photopheresis Plus Standard Therapy to Treat Chronic Graft-versus-Host Disease NCT00054613 | Mallinckrodt | Phase 2 |
| Completed | Sargramostim in Reducing Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplantat NCT00053157 | Roswell Park Cancer Institute | N/A |
| Completed | Hydroxychloroquine in Treating Patients With Newly Diagnosed Chronic Graft-Versus-Host Disease NCT00031824 | Children's Oncology Group | Phase 3 |
| Completed | Sirolimus as Secondary Therapy in Chronic Graft-Versus-Host Disease Not Responding To Prior Treatment NCT00079183 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Beclomethasone Plus Prednisone in Treating Patients With Graft-Versus-Host Disease NCT00043147 | Memorial Sloan Kettering Cancer Center | Phase 3 |
| Active Not Recruiting | Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders NCT00544115 | City of Hope Medical Center | Phase 2 |
| Unknown | Study of Allogeneic Bone Marrow and T-Cell Depleted, CD34+ Peripheral Blood Stem Cell Transplantation in Patie NCT00017654 | Northwestern Memorial Hospital | N/A |
| Completed | Compassionate Use of Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Gastrointestina NCT00055666 | Roswell Park Cancer Institute | N/A |
| Completed | Methylprednisolone With or Without Daclizumab in Treating Patients With Acute Graft-Versus-Host Disease NCT00053976 | Dana-Farber Cancer Institute | Phase 3 |
| Completed | Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Advanced Hematologi NCT00014469 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Completed | Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Mantle Cel NCT00006747 | Alliance for Clinical Trials in Oncology | Phase 2 |
| Completed | Allogeneic Transplantation From Related Haploidentical Donors NCT00185692 | Stanford University | Phase 2 |
| Completed | Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Esophagus, Stomach, Small Intestine, NCT00010283 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Unknown | Pilot Study of Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients With Life Threatening Hemop NCT00006056 | Fairview University Medical Center | N/A |
| Terminated | Allogeneic Bone Marrow Transplantation in Patients With Primary Immunodeficiencies NCT00006054 | Fairview University Medical Center | N/A |
| Unknown | Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases NCT00006055 | Fairview University Medical Center | N/A |
| Completed | Treatment of Bone Marrow to Prevent Graft-Versus-Host Disease in Patients With Acute or Chronic Leukemia Under NCT00004255 | Chimeric Therapies | Phase 2 / Phase 3 |
| Completed | Bone Marrow Transplantation With Specially Treated Bone Marrow in Treating Patients With Hematologic Cancer Th NCT00005988 | Dana-Farber Cancer Institute | Phase 1 |
| Terminated | Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer NCT00290628 | Masonic Cancer Center, University of Minnesota | N/A |
| Completed | Stem Cell Transplantation in Treating Patients With Hematologic Cancer NCT00004904 | Northwestern University | Phase 1 |
| Completed | Bone Marrow and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer NCT00004232 | Northwestern University | Phase 1 |
| Completed | Study of MEDI 507 in the Treatment of Pediatric Patients NCT00813618 | MedImmune LLC | Phase 1 |
| Completed | Thalidomide in Treating Patients With Chronic Graft-Versus-Host Disease Following Bone Marrow Transplant NCT00003894 | Roswell Park Cancer Institute | Phase 2 |
| Completed | Trial for Evaluation of Safety of Escalating Dose Levels of MEDI-507 in Patients for Treatment of at Least Gra NCT00806208 | MedImmune LLC | Phase 1 |
| Completed | Bone Marrow Transplantation in Treating Patients With Hematologic Cancer NCT00003398 | University of Maryland, Baltimore | Phase 4 |
| Completed | Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Other Hematologic or Meta NCT00003662 | Roswell Park Cancer Institute | Phase 2 |
| Completed | Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologi NCT00003661 | Roswell Park Cancer Institute | Phase 2 |
| Completed | Study of the Pharmacokinetics of Mycophenolate Mofetil in Patients Who Have Undergone Orthotopic Liver Transpl NCT00007059 | National Center for Research Resources (NCRR) | N/A |
| Completed | Study of MEDI-507 in With Steroid-Resistant Acute Graft-Versus-Host Disease NCT00806728 | MedImmune LLC | Phase 1 |
| Completed | Umbilical Cord Blood Transplantation in Treating Patients With High-Risk Hematologic Cancer NCT00003335 | Case Comprehensive Cancer Center | Phase 2 |
| Completed | Graft-Versus-Host Disease in Treating Patients With Recurrent or Refractory Lymphoma or Hodgkin's Disease NCT00003414 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 3 |
| Completed | Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologi NCT00003270 | Roswell Park Cancer Institute | Phase 2 |
| Terminated | Removal of T Cells to Prevent Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation NCT00005641 | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 |
| Terminated | Prevention of Graft-Versus-Host Disease in Patients With Advanced Leukemia or Lymphoma Who Are Eligible for Pe NCT00003056 | Baxalta now part of Shire | Phase 3 |
| Terminated | Bone Marrow Transplantation in Treating Patients With Severe Aplastic Anemia or Rejection of Previous Bone Mar NCT00005852 | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 |
| Withdrawn | Bone Marrow Transplantation in Treating Patients With Leukemia NCT00006451 | Masonic Cancer Center, University of Minnesota | Phase 3 |
| Recruiting | Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives NCT00001529 | National Heart, Lung, and Blood Institute (NHLBI) | — |
| Withdrawn | Prevention of Graft-Versus-Host Disease in Patients With Hematologic Malignancies Who Are Receiving a Bone Mar NCT00002790 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Completed | Peripheral Stem Cell Transplantation Plus Filgrastim in Treating Patients With Acute or Chronic Myelogenous Le NCT00002833 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Graft-Versus-Host Disease Prevention in Treating Patients Who Are Undergoing Bone Marrow Transplantation NCT00002456 | Fred Hutchinson Cancer Center | Phase 3 |
| No Longer Available | Prochymal® Expanded Access for Adults Who Have Failed Steroid Treatment for Acute Graft Versus Host Disease (G NCT00826046 | Mesoblast, Inc. | — |
| Withdrawn | OTI-010 for Graft-Versus-Host Disease Prophylaxis in Treating Patients Who Are Undergoing Donor Peripheral Ste NCT00081055 | Mesoblast International Sàrl | Phase 2 |
| Unknown | Fludarabine in Treating Patients With Steroid-Resistant Chronic Graft- Versus-Host Disease NCT00004194 | Jonsson Comprehensive Cancer Center | Phase 1 / Phase 2 |
| Withdrawn | Donor Lymphocytes to Prevent Graft-Versus-Host Disease in Patients With Chronic Myeloid Leukemia NCT00004878 | Jonsson Comprehensive Cancer Center | Phase 2 |